⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444559 | 1.00 | — | — | |
| SCHEMBL825603 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28075566 | 0.97 | SLC6A1 (0.71) | — | |
| SCHEMBL21402234 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2743430 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2323610 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2721855 | 0.97 | SLC6A1 (0.71) | — | |
| Hydrochloric Acid SCHEMBL2743519 | 0.97 | — | — | |
| SCHEMBL17743445 | 0.97 | — | — | |
| Benzene SCHEMBL28167147 | 0.95 | SLC6A1 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | claimed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | claimed |
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | claimed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | claimed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | claimed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | claimed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | claimed |
| EP-2828257-A1 | ANTIBACTERIAL COMPOUNDS | Biota Europe Ltd (GB) | 2015-01-28 | — | — | EP | claimed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | claimed |
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | claimed |
| EP-2473505-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | claimed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | claimed |
| EP-2068878-A2 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-06-17 | — | — | EP | claimed |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | claimed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | claimed |
| WO-2008036540-A2 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | claimed |
| EP-1888565-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2006110884-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-10-19 | — | — | WO | claimed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| EP-4045036-B1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12565498-B2 | β-lactamase inhibitors and their preparation | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2026-03-03 | — | — | US | disclosed |
| EP-4045037-B1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12497383-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | SOPONPONG JAKAPUN (TH) | 2025-11-27 | — | — | US | disclosed |
| US-20250346598-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4622996-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | King's College London (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4620948-A1 | LIPID COMPOUND AND COMPOSITION FOR DELIVERY OF ACTIVE SUBSTANCE | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-09-24 | — | — | EP | disclosed |
| EP-4072671-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-12371433-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | AMGEN INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2025122811-A1 | M4 POSITIVE ALLOSTERIC MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4566675-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025111582-A1 | AZA-TETRACYCLIC OXAZEPINE INHIBITORS OF KRAS-G12D | GENENTECH, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250171443-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| CN-115925697-B | Small molecule immunoregulation inhibitor and pharmaceutical composition and application thereof | 昆药集团股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119613400-A | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12247026-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025029075-A1 | NOVEL BIPHENYL DERIVATIVE AS PD-L1 INHIBITOR | (주)아이랩 | 2025-02-06 | — | — | WO | disclosed |
| EP-4212529-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-112457331-B | Nitrogen-containing heterocyclic compound, preparation method, pharmaceutical composition and application thereof | 上海长森药业有限公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-4486734-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024242204-A1 | NOVEL COMPOUND OR SALT THEREOF, CATALYST, METHOD OF PREPARING NOVEL COMPOUND OR SALT THEREOF AND METHOD OF PREPARING MANNICH PRODUCT | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2024-11-28 | — | — | WO | disclosed |
| CN-114364683-B | Preparation and application of aromatic heterocyclic derivative as immunomodulator | 上海长森药业有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240376106-A1 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2024-11-14 | — | — | US | disclosed |
| CN-112135824-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20240336601-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | CHULALONG UNIVERSITY (TH) | 2024-10-10 | — | — | US | disclosed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12084443-B2 | Process of preparing a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| CN-112955435-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-115151544-B | Beta-lactamase inhibitor and preparation thereof | 宁夏农林科学院 | 2024-08-16 | — | — | CN | disclosed |
| CN-113072551-B | Nitrogen-containing biphenyl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-112566905-B | Substituted phenylpropenyl pyridine derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| WO-2024134466-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS, SUBSTITUTED HETEROARYLAMINE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| CN-118146132-A | Azacyclo metal halogen perovskite material and preparation method and application thereof | 吉林大学 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024114561-A1 | SPIRO-HETEROCYCLE SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2024-06-06 | — | — | WO | disclosed |
| WO-2024110757-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | KING'S COLLEGE LONDON (GB) | 2024-05-30 | — | — | WO | disclosed |
| CN-118084873-A | Spiro heterocycle substituted pyrimidine compound and preparation method and application thereof | 上海美悦生物科技发展有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4367118-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11976071-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240132495-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4355729-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Celgene Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20240124394-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024069448-A1 | SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-04-04 | — | — | WO | disclosed |
| CN-115003380-B | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2024018403-A1 | SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-01-25 | — | — | WO | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| US-11866429-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023250335-A1 | 1,4-DIPHENYL-1 H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1 H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | CHULALONGKORN UNIVERSITY (TH) | 2023-12-28 | — | — | WO | disclosed |
| US-20230406852-A1 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2023-12-21 | — | — | US | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230357219-A1 | PREPARATION OF BIARYL RING-LINKED AROMATIC HETEROCYCLIC DERIVATIVE AS IMMUNOMODULATOR AND USE THEREOF | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| EP-4267117-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230322731-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11780836-B2 | Process of preparing a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780836-B2 | Process of preparing a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780836-B2 | Process of preparing a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| CN-116685313-A | Indanyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4234016-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-112457329-B | Preparation and application of aromatic heterocyclic derivative as immunomodulator | 上海长森药业有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-116514802-A | Indoline immunoregulation inhibitor and pharmaceutical composition and application thereof | 昆药集团股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-4212529-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-111925367-B | Fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| EP-3894402-B1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086341-A1 | INHIBITORS OF KRAS | BIOMEA FUSION, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| CN-116115764-A | Tetrahydroimidazo [4,5-C ] pyridine derivatives as PD-L1 internalization inducers | 因赛特公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023077040-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-111808007-B | Preparation method of chiral 3-substituted pyrrolidine derivative | 青岛贞开生物医药技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| CN-115925697-A | Small molecule immunoregulation inhibitor and pharmaceutical composition and application thereof | 昆药集团股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3921327-B1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX INC (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| US-20230089087-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | OXFORD FINANCE LLC | 2023-03-23 | — | — | US | disclosed |
| EP-4146650-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | Ningxia Academy of Agriculture and Forestry Sciences (CN) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2023023255-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-4126863-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126839-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2023-01-26 | — | — | US | disclosed |
| CN-115605488-A | Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022266162-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-3774791-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-110267953-B | Tetrahydroimidazo [4,5-C ] pyridine derivatives as inducers of PD-L1 internalization | 因赛特公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20220395553-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. | 2022-12-15 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| CN-115397818-A | Aminopyrimidine derivatives and their use as modulators of arene receptors | 东亚ST株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-20220372031-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-11-24 | — | — | US | disclosed |
| CN-113248492-B | Heterocycle substituted nitrogen-containing six-membered heterocyclic derivative, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| EP-4083032-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2022-11-02 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220332774-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-4072671-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| US-11471436-B2 | Dihydronaphthalene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| US-20220324912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324925-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324911-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324909-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| CN-115151544-A | Beta-lactamase inhibitors and preparation thereof | 宁夏农林科学院 | 2022-10-04 | — | — | CN | disclosed |
| US-20220305079-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20220306691-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11453701-B2 | Tau aggregation peptide inhibitors | ADRX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4058465-A1 | CXCR4 ANTAGONIST PEPTIDES | Cohbar Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-112812113-B | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-3558985-B1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114989176-A | Imidazopyridazine derivative and application thereof | 深圳市新樾生物科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003380-A | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-4045037-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022166991-A1 | INDOLINE COMPOUND | 南京明德新药研发有限公司 | 2022-08-11 | — | — | WO | disclosed |
| EP-3558990-B1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORP (US) | 2022-08-10 | — | — | EP | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220226484-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022147302-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2022-07-07 | — | — | WO | disclosed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| WO-2022140555-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220195017-A1 | PATHOGEN BINDING METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114585359-A | Heteroaryl benzidines for the treatment of PD-L1 diseases | 凯莫森特里克斯股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220169639-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| CN-114555080-A | Heteroaryl biphenylamines useful for the treatment of PD-L1 disease | 凯莫森特里克斯股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220144830-A1 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2022-05-12 | — | — | US | disclosed |
| US-20220144830-A1 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2022-05-12 | — | — | US | disclosed |
| WO-2022099018-A1 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-108349969-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阵列生物制药公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114364685-A | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof | 上海长森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364683-A | Preparation and application of aromatic heterocyclic derivative as immunomodulator | 上海长森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3558963-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3967687-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022047603-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-113880833-A | Biphenyl polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113801163-A | II-type pyruvate kinase inhibitor based on organic arsenic and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2021-12-17 | — | — | CN | disclosed |
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-16 | — | — | US | disclosed |
| US-20210380584-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-12-09 | — | — | US | disclosed |
| US-20210363187-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2021-11-25 | — | — | US | disclosed |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | GILEAD SCIENCES, INC. | 2021-11-18 | — | — | US | disclosed |
| WO-2021226262-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021211784-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| EP-3894402-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| CN-113518784-A | Therapeutic peptides | 科巴公司 | 2021-10-19 | — | — | CN | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| US-11124511-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| US-11117930-B2 | Peptide inhibitors of transcription factor aggregation | ADRX, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11111271-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-113248492-A | Heterocycle substituted nitrogen-containing six-membered heterocycle derivative, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2021155194-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| CN-113072551-A | Nitrogen-containing biphenyl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021116703-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| CN-112955435-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210163409-A1 | ALTERNATE PROCESSES FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES | Dr Reddys Laboratories Ltd (IN) | 2021-06-03 | — | — | US | disclosed |
| US-11021709-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2021097256-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021093817-A1 | IMMUNOMODULATORY COMPOUNDS, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2021-05-20 | — | — | WO | disclosed |
| CN-112812113-A | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20210130347-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130325-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| CN-112566905-A | Substituted phenyl propenyl pyridine derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2021047556-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 上海长森药业有限公司 | 2021-03-18 | — | — | WO | disclosed |
| WO-2021047553-A1 | AROMATIC HETEROCYCLIC COMPOUND HAVING TRICYCLIC STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海长森药业有限公司 | 2021-03-18 | — | — | WO | disclosed |
| WO-2021047547-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 上海长森药业有限公司 | 2021-03-18 | — | — | WO | disclosed |
| CN-112457329-A | Preparation and application of aromatic heterocyclic derivative as immunomodulator | 上海长森药业有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112457331-A | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof | 上海长森药业有限公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2021030799-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030792-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030752-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030794-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030469-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-3774791-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3228615-B1 | DIHYDRONAPHTHALENE DERIVATIVES USEFUL IN THE TREATMENT OF S1P5-MEDIATED DISEASES | ONO PHARMACEUTICAL CO (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | disclosed |
| CN-112135824-A | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200397893-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2020-12-24 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-20200362350-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-19 | — | — | US | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| CN-111925367-A | Fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| CN-111808007-A | Preparation method of chiral 3-substituted pyrrolidine derivative | 青岛贞开生物医药技术有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-10806785-B2 | Immunomodulator compounds and methods of use | INCYTE CORPORATION (US) | 2020-10-20 | — | — | US | disclosed |
| CN-105849102-B | N- (1-hydroxy-3 (pyrrolidinyl) propan-2-yl) pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | 生物马林药物股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10800768-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200262834-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200255424-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-08-13 | — | — | US | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20200216495-A1 | TAU AGGREGATION PEPTIDE INHIBITORS | ADRX, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10704049-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-07-07 | — | — | US | disclosed |
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
| EP-3668886-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | Adrx, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2020120528-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200181197-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2020-06-11 | — | — | US | disclosed |
| US-10669271-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200157094-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20200062804-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200031900-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| CN-110582493-A | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3558963-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558990-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019191707-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190300524-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| CN-110267953-A | Tetrahydroimidazo [4,5-C ] pyridine derivatives as inducers of PD-L1 internalization | 因赛特公司 | 2019-09-20 | — | — | CN | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3519431-A1 | THERAPEUTIC MOTS-C RELATED PEPTIDES | Cohbar Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190169125-A1 | CONCISE PROCESS FOR PREPARING 3-PYRROLIDINE CARBOXYLIC ACID DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| CN-109761952-A | A kind of resorcinol methyl ether derivative and application thereof containing substituted biphenyl | 南方医科大学 | 2019-05-17 | — | — | CN | disclosed |
| US-20190135777-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-09 | — | — | US | disclosed |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127374-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-10273283-B2 | Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3464278-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| EP-2068878-B1 | RHO KINASE INHIBITORS | AERIE PHARMACEUTICALS INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190077850-A1 | PATHOGEN BINDING METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-03-14 | — | — | US | disclosed |
| WO-2019036725-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | ADRX, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| CN-109311860-A | For treating or preventing the Xanthone derivative of hepatitis type B virus disease | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2019016745-A1 | ALTERNATE PROCESSES FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-01-24 | — | — | WO | disclosed |
| US-10174027-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-10160744-B2 | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-12-25 | — | — | US | disclosed |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180344723-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2018-12-06 | — | — | US | disclosed |
| EP-2582715-B1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10138243-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-10118927-B2 | Substituted piperidin-4-amino-type compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180282730-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018156892-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180214472-A1 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | VYOME BIOSCIENCES, PVT. LTD. (IN) | 2018-08-02 | — | — | US | disclosed |
| CN-108349969-A | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阵列生物制药公司 | 2018-07-31 | — | — | CN | disclosed |
| WO-2018136935-A1 | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2018-07-26 | — | — | WO | disclosed |
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180186790-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186791-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119286-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119224-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-10000756-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| EP-3322706-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
| CN-105330576-B | The phosphate analogs of aryl bicyclic sphingol 1 | 比奥根MA公司 | 2018-04-10 | — | — | CN | disclosed |
| WO-2018064098-A1 | THERAPEUTIC MOTS-C RELATED PEPTIDES | COHBAR, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-9907812-B2 | Conjugate-based antifungal and antibacterial prodrugs | VYOME BIOSCIENCES PVT. LTD. (IN) | 2018-03-06 | — | — | US | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| WO-2017202798-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| US-9827258-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827258-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170327439-A1 | DIHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| US-9790262-B2 | Compositions comprising glucagon analogs and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3228615-A1 | DIHYDRONAPHTHALENE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2017-10-11 | — | — | EP | disclosed |
| WO-2017157929-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-09-21 | — | — | WO | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260158-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-09-14 | — | — | US | disclosed |
| CN-105026360-B | S1P conditioning agents | 比奥根MA公司 | 2017-08-25 | — | — | CN | disclosed |
| US-20170239280-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170239280-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170239280-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170217889-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217889-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2017-07-27 | — | — | US | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170183390-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-06-29 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| US-20170145420-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-05-25 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-9630940-B2 | Process for producing dihydro-2H-pyran derivatives | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9630940-B2 | Process for producing dihydro-2H-pyran derivatives | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| EP-2885282-B1 | PROCESS FOR PRODUCING DIHYDRO-2H-PYRAN DERIVATIVES | OKINAWA INST SCIENCE & TECH SCHOOL CORP (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-9593141-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9572824-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572824-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572824-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9540620-B2 | Methods and compositions for modulating G-alpha-Q signaling | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-104619709-B | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2016176636-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2748182-B1 | PEPTIDE NANOPARTICLES AND USES THEREOF | HARVARD COLLEGE (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160251328-A1 | PROCESS FOR PRODUCING DIHYDRO-2H-PYRAN DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251328-A1 | PROCESS FOR PRODUCING DIHYDRO-2H-PYRAN DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| CN-105849102-A | N- (1-hydroxy-3 (pyrrolidinyl) propan-2-yl) pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | 生物马林药物股份有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-9346780-B2 | Process for producing dihydro-2H-pyran derivatives | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9346780-B2 | Process for producing dihydro-2H-pyran derivatives | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. | 2016-05-12 | — | — | US | disclosed |
| US-9315546-B2 | Growth hormone secretatogue receptor antagonists and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2016-04-19 | — | — | US | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| WO-2016014982-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-9243037-B2 | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity | TRUSTEES OF BOSTON COLLEGE (US) | 2016-01-26 | — | — | US | disclosed |
| US-9186367-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BOIGEN MA INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186367-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BOIGEN MA INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186367-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BOIGEN MA INC. (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015168465-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20150274657-A1 | PYRROLIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| EP-2916833-A1 | METHODS OF TREATING LIVER DISEASES | Zafgen, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150246896-A1 | PROCESS FOR PRODUCING DIHYDRO-2H-PYRAN DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246896-A1 | PROCESS FOR PRODUCING DIHYDRO-2H-PYRAN DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150239936-A1 | GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY | TRUSTEES OF BOSTON COLLEGE | 2015-08-27 | — | — | US | disclosed |
| EP-2903966-A1 | PYRROLIDINES | Merck Patent GmbH (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
| US-20150218252-A1 | SELF-ASSEMBLING PEPTIDES, PEPTIDE NANOSTRUCTURES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-08-06 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| US-20150141398-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015065937-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-2461683-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2461683-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20150111954-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-8975398-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2828257-A1 | ANTIBACTERIAL COMPOUNDS | Biota Europe Ltd (GB) | 2015-01-28 | — | — | EP | disclosed |
| US-20140364595-A1 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | VYOME BIOSCIENCES (IN) | 2014-12-11 | — | — | US | disclosed |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8828928-B2 | Amphiphilic peptides and peptide particles | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| WO-2014102590-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| EP-2748182-A1 | PEPTIDE NANOPARTICLES AND USES THEREOF | President and Fellows of Harvard College (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| CN-103857440-A | Conjugate-based antifungal and antibacterial prodrugs | VYOME BIOSCIENCES | 2014-06-11 | — | — | CN | disclosed |
| WO-2014071368-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2723452-A2 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | Vyome Biosciences Pvt Ltd (IN) | 2014-04-30 | — | — | EP | disclosed |
| WO-2014053210-A1 | PYRROLIDINES | MERCK PATENT GMBH (DE) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014014613-A2 | SELF-ASSEMBLING PEPTIDES, PEPTIDE NANOSTRUCTURES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20130303509-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130267694-A1 | PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS | THERACOS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267694-A1 | PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS | THERACOS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2013149362-A1 | 1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013131901-A1 | BENZODIOXANES IN COMBINATION WITH OTHER ACTIVES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2013-07-04 | — | — | US | disclosed |
| WO-2013071049-A1 | GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY | TRUSTEES OF BOSTON COLLEGE (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2582715-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators of the Tulane Educational Fund (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130064895-A1 | Amphiphilic Peptides and Peptide Particles | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2013036674-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20130060022-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060022-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2013028843-A1 | PEPTIDE NANOPARTICLES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012177986-A2 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | VYOME BIOSCIENCES (IN) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531487-A1 | ARYL BENZYLAMINE COMPOUNDS | Novartis AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2012101063-A1 | N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101064-A1 | N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2473505-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| CN-102548409-A | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC INC | 2012-07-04 | — | — | CN | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| EP-2461683-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011149841-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011095452-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-7858622-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7858622-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-7598392-B2 | 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-10-06 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| EP-1549640-A4 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
| EP-1581509-A4 | 1-(AMINO)INDANES AND (1,2-DIHYDRO-3-AMINO)-BENZOFURANS, BENZOTHIOPHENES AND INDOLES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1888565-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070259847-A1 | 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
| WO-2007062316-A2 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR ANTI-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062316-A2 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR ANTI-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117986-A1 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2007-05-24 | — | — | US | disclosed |
| US-20070117986-A1 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2007-05-24 | — | — | US | disclosed |
| US-20070117986-A1 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2007-05-24 | — | — | US | disclosed |
| US-7220734-B2 | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7199142-B2 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2007020261-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006110884-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060161005-A1 | 1-(Amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists | MERCK SHARP & DOHME CORP. | 2006-07-20 | — | — | US | disclosed |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1581509-A2 | 1-(AMINO)INDANES AND (1,2-DIHYDRO-3-AMINO)-BENZOFURANS, BENZOTHIOPHENES AND INDOLES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1549640-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004058149-A2 | 1-(AMINO)INDANES AND (1,2-DIHYDRO-3-AMINO)-BENZOFURANS, BENZOTHIOPHENES AND INDOLES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004035538-A1 | PROCESS FOR MAKING AZETIDINE-3-CARBOXYLIC ACID | MERCK & CO., INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003105771-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105771-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |